Newsmakers

CytoDyn (OTC: CYDY) Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)

VANCOUVER, Washington, Mar 09, 2020  — Coronavirus Can Quickly Progress to Severe Pneumonia and Even Death Due to Immune Hyperactivity Including Acute Respiratory Distress Syndrome (ARDS); CytoDyn’s Trial Focuses on Patients Who Develop Mild-To-Moderate Respiratory […]

Newsmakers

NexTech’s Revolutionary 3D AR Capture App “ARitize 360” Now Available for Early Access Signup

The company’s new CaptureAR App to facilitate the mass adoption of augmented reality (AR) NEW YORK and TORONTO, March 05, 2020  — NexTech AR Solutions (the “Company” or “NexTech”) (otcqb:NEXCF) (NTAR)(N29) NexTech, the industry leader […]

Healthcare

CytoDyn (OTC: CYDY) Treats First Patient with Leronlimab in Phase 2 Trial for GvHD under Modified Trial Protocol

VANCOUVER, Washington, Mar 04, 2020 CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the treatment of […]

Healthcare

CytoDyn (OTC: CYDY) Reports Remarkable Outcomes for Additional Cancer Patients in mTNBC Trial; Following an Overwhelming Community Response, CytoDyn Expects to Enroll More Than 20 Patients in its 22 Solid Tumor Cancer Trial in the Next 60 Days

VANCOUVER, Washington, March 02, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive […]

Healthcare

CytoDyn to Hold Conference Call for Updates on Filing Phase 2 Trial with FDA for Treatment of Coronavirus in U.S., Status of BLA, Breakthrough Therapy Designation, Basket Trial for 22 Solid Tumor Cancers and Licensing Opportunities in Several Countries

VANCOUVER, Washington, Feb 28, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader […]

Newsmakers

NexTech (OTC: NEXCF)Lands Four New WebAR Customers

New customer wins expected to scale rapidly with launch of NexTech’s CaptureAR technology NEW YORK and TORONTO, Feb. 27, 2020 — NexTech AR Solutions (NexTech) (otcqb:NEXCF) (NTAR)(N29), the leader in augmented reality for eCommerce and AR learning […]

Newsmakers

Imagination Park Technology (OTC: IPNFF) Announces Closing of Oversubscribed Convertible Debenture for $1,500,000

Vancouver, CANADA– February 26, 2020 – Imagination Park Technologies Inc. (CSE: IP) (OTC: IPNFF) is pleased to announce that it has closed its previously announced convertible debenture for an oversubscribed total amount of $1,500,000. The Company intends […]

Newsmakers

CytoDyn (OTC: CYDY) Receives Institutional Review Board Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers

VANCOUVER, Washington, Feb 21, 2020  — Results from mTNBC and MBC studies continues to be positive with the first patient now at almost five months of treatment showing zero CTC, EMT and CAML. Seven patients […]